Start Belief updating and learning in semi qualitative probabilistic networks

Belief updating and learning in semi qualitative probabilistic networks

The raise represents the largest to date for the Louisville, Ky.-based company, topping last year’s $47 million series D.

This research was (partly) supported by the Netherlands Organisation for Scientific Research (NWO).

We then discuss learning: we consider a maximum likelihood method that generates point estimates given a SQPN and empirical data, and we describe a Bayesian-minded method that employs the Imprecise Dirichlet Model to generate set-valued estimates.

LOUISVILLE, KY., August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that its complement C3 inhibitor, APL-2, met its primary endpoint in a Phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).

Existing investors Morningside Ventures, Cormorant Asset Management, Venbio Global Strategic Fund and Epidarex Capital also participated in the financing.